Harbor Capital Advisors Inc. Has $2.30 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Harbor Capital Advisors Inc. grew its position in Natera, Inc. (NASDAQ:NTRA) by 261.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 18,124 shares of the medical research company’s stock after buying an additional 13,106 shares during the period. Harbor Capital Advisors Inc.’s holdings in Natera were worth $2,301,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the period. Moss Adams Wealth Advisors LLC boosted its position in shares of Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. Private Advisor Group LLC boosted its position in shares of Natera by 5.2% in the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after purchasing an additional 135 shares during the last quarter. Lake Street Advisors Group LLC boosted its position in shares of Natera by 7.4% in the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock worth $286,000 after purchasing an additional 156 shares during the last quarter. Finally, Quarry LP boosted its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NTRA shares. Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Stephens restated an “overweight” rating and issued a $125.00 price target on shares of Natera in a research report on Friday, August 9th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Leerink Partners lifted their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $125.69.

Natera Stock Performance

NTRA opened at $123.44 on Tuesday. The business’s 50-day moving average price is $123.40 and its two-hundred day moving average price is $112.53. Natera, Inc. has a 1 year low of $40.61 and a 1 year high of $133.54. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of -50.38 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter last year, the business posted ($0.97) EPS. The company’s revenue for the quarter was up 58.1% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at approximately $8,706,208.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at approximately $8,706,208.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 5,583 shares of Natera stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,164 shares of company stock valued at $6,157,291. 7.60% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.